Esperion names pharma CFO to board

ANN ARBOR—The Ann Arbor cholesterol-lowering drug developer Esperino Therapeutics Inc. (NASDAQ: ESPR) announced the appointment of Alan Fuhrman as a Class III director, with a term expiring at the 2022 meeting of stockholders.

“On behalf of the Lipid Management team and our directors, I am very pleased to welcome Alan to the Esperion board. His extensive financial leadership experience will be extremely valuable as Esperion transitions to both developing and commercializing oral, LDL-C lowering medicines,” said Tim Mayleben, Esperion president and CEO. “With the recent U.S. approvals of the Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) tablets, we are poised to deliver on the commercial promise of our medicines while continuing to advance the development of oral, once-daily LDL-C lowering medicines for the millions of patients in need.  Alan’s accounting and financial acumen will help the company to successfully and responsibly navigate these opportunities for our shareholders.”

Fuhrman brings over 20 years of executive financial experience in biotechnology, medical devices, technology and services. He is currently CFO of Anphlyx Pharmaceuticals, a biotech company developing new products for infection. He previously served as CFO of Mirna Therapeutics, a clinical-stage microRNA company that merged with Synlogic in August 2017, and at Ambit Biosciences, where he helped lead the company through its initial public offering to its sale to Daiichi Sankyo in 2014. He is also a member of the board of directors for SpringWorks Therapeutics and Checkmate Pharmaceuticals.

“I’m confident in the mission of the Esperion team to deliver lipid management for everybody,” Fuhrman said. “There are millions of patients that stand to benefit from the company’s ability to successfully execute on its commercial strategy.”

Esperion is developing a new class of cholesterol-reducing drugs that work for people who experience side effects like muscle weakness from today’s statin drugs. High levels of LDL-C, the so-called bad cholesterol, can lead to a buildup of fat in and on artery walls that can lead to heart attack and stroke, the leading causes of death around the world. For more information, visit


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.